Aurobindo Pharma on Monday reported a marginal dip in its consolidated profit after tax to Rs 903 crore for the fourth quarter ended March 2025. The Hyderabad-based drug maker posted a profit after tax (PAT) of Rs 907 crore in the January-March quarter of FY24.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets